PODD vs TNDM
PODD: Insulet provides the Omnipod system, a revolutionary tubeless, wearable insulin pump platform that simplifies diabetes management through automated insulin delivery. TNDM: Tandem Diabetes Care provides advanced, consumer-focused automated insulin delivery systems designed to simplify diabetes management.
Side-by-side fundamentals
| Metric | PODD | TNDM | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $134.47 | $15.68 | |
| Market cap | $9.3B | $1.1B | |
| P/E as of 2026-10-08 | 25.16 | n/a | |
| Net margin FY2025, SEC XBRL | +9.1% | -20.2% | PODD higher |
| Gross margin FY2025, SEC XBRL | +71.6% | +53.8% | PODD higher |
| Operating margin FY2025, SEC XBRL | +17.5% | -18.5% | PODD higher |
| ROE FY2025, SEC XBRL | +16.3% | -131.9% | PODD higher |
| ROA FY2025, SEC XBRL | +7.7% | -23.2% | PODD higher |
| Debt / equity as of 2026-09-02 | 0.63 | 4.66 | PODD lower |
| Revenue growth (YoY) as of 2026-09-02 | +29.4% | +4.0% | PODD higher |
| Revenue CAGR (3y) SEC XBRL | +27.5% | +8.2% | PODD higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.64 | 1.11 | |
| 1-year return as of 2026-10-08 close | -57.4% | +2.2% | TNDM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.